RecruitingPHASE2, PHASE3NCT04708054

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Uday R Popat
M.D. Anderson Cancer Center
Intervention
Busulfan(drug)
Enrollment
324 enrolled
Eligibility
18-70 years · All sexes
Timeline
20212027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04708054 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials